Skip to main content

Table 1 Demographic and disease characteristics at vaccination, and prevaccination- and postvaccination GML in RA patients on different treatments and controls

From: Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis

Treatment groups Rituximab monotherapy Rituximab + MTX Abatacept (n = 17) Tocilizumab (n = 16) MTX Controls
      (n = 85) (n = 86)
  (n = 29) (n = 26)     
Female gender, % 72% 62% 88% 81% 79% 45%
Age, years, mean (SD) (range) 68.9 (9) (50 to 87) 59.9 (12) (39 to 85) 56.6 (13) (29 to 75) 55.6 (12) (27 to 72) 61.5 (14) (24 to 85) 51.6 (12) (22 to 75)
Disease duration, years mean (SD) (range) 21.3 (14) (0 to 57) 14.5 (12) (2 to 50) 14.9 (2.9) (2 to 46) 13.8 (12) (0 to 43) 11.4 (10) (0 to 40) 12.7 (12) (0 to 45)
HAQ, 0 to 3 1.2 (0.8) 1.1 (0.6) 1.4 (0.6) 1.5 (0.7) 0.7 (0.6) 0.5 (0.5)
DAS, 0 to 7 3.9 (1.2) 3.9 (1.1) 4.9 (1.2) 3.6 (1.7) 3.7 (1.2) 3.0 (1.1)
Ongoing MTX, yes, % ---- 100% 76% 56% 100% ----
MTX mg/week, mean ---- 17.2 15.6 14.7 16.4 ----
Ongoing prednisolone,
yes, %
55.2% 65.4% 70.0% 53.3% 31.3% 6.2%
Prednisolone, mg/week, mean 30.9 35.4 32.7 27.5 14.0% 2.2
CRP mg/L, mean 15.8 6.4 9.7 3.9 8.9 7.7
TJC28, mean (range) 3.5 (0 to 23) 4.7 (0 to 19) 8.2 (0 to 20) 7.6 (0 to 28) 2.8 (0 to 12) 1.9 (0 to 18)
SJC, mean (range) 3.4 (0 to 15) 3.9 (0 to 13) 4.8 (0 to 12) 5.1 (0 to 25) 2.0 (0 to 11) 0.4 (0 to 5)
RF-positive, % 93% 89% 88% 81% 78% NA
Anti-CCP-positive, % 86% 92% 82% 63% 75% NA
Smoker, % 14% 31% 19% 14% 19% 12%
IgG at vaccination, g/L, mean (SD) 8.2 (2.9) 8.0 (2) 9.1 (1.9) 8.7 (2.6) 9.7 (2.5) 9.9 (2.1)
IgM at vaccination, g/L, mean (SD) 0.8 (0.7) 0.9 (0.5) 1.3 (0.7) 1.1 (0.5) 1.1 (0.6) 1.0 (0.6)
IgA at vaccination, g/L, mean (SD) 2.3 (1.3) 2.4 (0.9) 2.9 (1.3) 2.5 (0.9) 2.5 (1.1) 2.5 (1.1)
Pneumococcal vaccine previously, % 24.1% 23.1% 11.8% 6.3% 10.6% 1.2%
Last biologic treatment before vaccination, days, mean (range) 71 (0 to 501) 102 (0 to 894) 8 (0 to 26) 7 (0 to 34) NA NA
Prevaccination antibody levels for 6B, mg/L, GML (95% CI) 0.3 (0.2-0.6) 0.4 (0.2, 0.8) 0.6 (0.3, 1.4) 0.4 (1.0, 1) 2.0 (1.4, 2.8) 2.9 (2.1, 4.0)
Postvaccination antibody levels for 6B, mg/L, GML (95% CI) 0.4 (0.2-0.8) 0.4 (0.2, 0.8) 1.1 (0.4, 2.7) 1.7 (0.5, 5.8) 3.5 (2.5, 4.9) 9.5 (6.7, 13.6)
Prevaccination antibody levels for 23F, mg/L, GML (95% CI) 0.2 (0.1, 0.4) 0.3 (0.1, 0.5) 0.4 (0.2, 0.9) 0.2 (0.1, 0.5) 0.7 (0.5, 1.1) 0.97 (0.7, 1.4)
Postvaccination antibody levels for 23F, mg/L, GML (95% CI) 0.3 (0.2, 0.6) 0.4 (0.2, 0.8) 1.1 (0.6, 2.3) 2.2 (0.9-5.3) 1.9 (1.4, 2.6) 6.4 (4.5, 9.1)
  1. Controls were patients with spondyloarthropathy on non-steroidal anti-inflammatory drugs/analgesics. GML, geometric mean antibody levels; RA, rheumatoid arthritis; MXT, methotrexate; HAQ, health assessment questionnaire; DAS, disease activity score; TJC, tender joint count; SJC, swollen joint count; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide antibody; NA, not applicable.